How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Dr. Abdel-Wahab discusses the effects of SAMHD1 depletion on the response to multiple chemotherapeutic agents.
Dr. Abdel-Wahab studies the role of the epitranscriptome in the context of normal and malignant hematopoiesis.
Dr. Abdel-Wahab and Dr. Taylor review the progress made during 2016 in understanding the molecular underpinnings of acute myeloid leukemia (AML) as well as in the use of precision medicine for patients with AML.
Dr. Abdel-Wahab and Dr. Taylor study the biology of mutant IDH1 in a myeloid-specific context with the additive effect of aging, and highlight one of the TET2-independent consequences of 2HG.
Dr. Abdel-Wahab and Dr. Taylor cover a study that measures the safety of combination ABT-199 and hypomethylating agents in older adults with acute myelogenous leukemia (AML), who are treatment-naive and not eligible for standard induction therapy.
Drs. Abdel-Wahab and Taylor look at a study about the use of core circadian clock genes in anti-leukemic therapy.
Dr. Abdel-Wahab and Dr. Taylor shed light on two recent studies that have identified synthetic lethal interactions created by deletion of genes in the neighboring genome around the 9p21 locus. Deletion of the 9p21 locus is one of the most common genetic events in cancer, yet there is no therapy that targets cancer cells with this alteration.
Drs. Abdel-Wahab and Taylor look at several studies that have provided a set of techniques, tools, and knockout cells, which can help provide insight into new functions of our genome and new therapies to target cancer.
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology